{"url_path":"/sec/neup/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1191070/0001193125-26-225442-index.html","accession_number":"0001193125-26-225442","cik":"0001191070","ticker":"NEUP","issuer_name":"Neuphoria Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1191070/0001193125-26-225442-index.html","primary_entity_key":"0001191070","primary_entity_name":"Neuphoria Therapeutics Inc."},"word_count":483,"has_tables":true,"body_markdown":"10-Q\n\n0001191070false2026--06-30Q3http://www.neuphoriatx.com/20260331#InterimChiefExecutiveOfficerMember0001191070us-gaap:RetainedEarningsMember2024-09-300001191070neup:ContingentConsiderationInABusinessCombinationMember2026-03-310001191070neup:FreestandingFinancialInstrumentsAccompanyingWarrantLiabilityMember2024-06-3000011910702024-07-012025-06-300001191070us-gaap:RetainedEarningsMember2024-06-3000011910702021-06-300001191070srt:MaximumMember2025-10-310001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001191070us-gaap:RestrictedStockUnitsRSUMember2026-01-202026-01-200001191070neup:TwentyTwentyFourAccompanyingADSWarrantsMember2026-03-310001191070us-gaap:RetainedEarningsMember2024-07-012024-09-300001191070neup:TwoThousandTwentyFourEquityIncentivePlanMembersrt:MaximumMember2024-12-310001191070us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001191070us-gaap:AdditionalPaidInCapitalMember2025-10-012025-12-310001191070us-gaap:CommonStockMember2024-06-300001191070neup:WarrantsToPurchaseCommonStockMember2025-01-012025-03-310001191070us-gaap:CommonStockMember2026-03-310001191070neup:BionomicsLimitedMember2025-07-012026-03-310001191070us-gaap:RetainedEarningsMember2026-03-3100011910702024-07-012025-03-310001191070neup:DanforthAdvisorsMember2025-07-012026-03-310001191070us-gaap:CommonStockMember2024-12-310001191070neup:RightsPlanMemberus-gaap:PreferredStockMember2025-10-270001191070us-gaap:FairValueMeasurementsRecurringMember2026-03-3100011910702025-07-012025-09-300001191070us-gaap:RestrictedStockUnitsRSUMember2026-03-3100011910702025-10-3100011910702026-05-140001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100011910702025-10-012025-12-310001191070us-gaap:CommonStockMember2025-01-012025-03-310001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001191070us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001191070neup:OptionsToPurchaseCommonStockMember2025-01-012025-03-310001191070us-gaap:RetainedEarningsMember2025-06-300001191070us-gaap:CommonStockMember2025-10-012025-12-310001191070neup:WarrantsToPurchaseCommonStockMember2026-01-012026-03-3100011910702025-07-012026-03-310001191070neup:WarrantsToPurchaseCommonStockMember2025-07-012026-03-3100011910702025-06-300001191070neup:TwentyTwentyFourAccompanyingADSWarrantsMember2025-07-012026-03-310001191070neup:NeuphoriaTherapeuticsIncMember2025-07-012026-03-310001191070srt:MaximumMember2025-01-012025-03-310001191070neup:DanforthAdvisorsMember2025-01-012025-03-310001191070us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001191070us-gaap:SeriesAPreferredStockMember2025-07-012026-03-310001191070us-gaap:CommonStockMember2024-09-300001191070neup:WGPartnersLLPMember2025-07-012026-03-310001191070us-gaap:CommonStockMember2024-10-012024-12-310001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-10-012025-12-310001191070us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001191070us-gaap:RetainedEarningsMember2025-01-012025-03-310001191070us-gaap:CommonStockMember2025-07-012025-09-300001191070us-gaap:RetainedEarningsMember2025-12-310001191070us-gaap:CommonStockMember2025-06-300001191070neup:DanforthAdvisorsMember2026-01-012026-03-310001191070us-gaap:CommonStockMember2025-09-300001191070us-gaap:RetainedEarningsMember2024-10-012024-12-310001191070us-gaap:AdditionalPaidInCapitalMember2024-06-300001191070us-gaap:AdditionalPaidInCapitalMember2026-03-310001191070neup:CancerStemCellTechnologyMember2026-03-310001191070us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001191070us-gaap:CommonStockMember2024-07-012024-09-300001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001191070neup:StockSubscriptionReceivableMember2025-06-300001191070us-gaap:FairValueMeasurementsRecurringMember2025-06-300001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001191070us-gaap:AdditionalPaidInCapitalMember2024-09-300001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001191070us-gaap:RetainedEarningsMember2025-03-310001191070us-gaap:AdditionalPaidInCapitalMember2024-12-310001191070us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001191070neup:StockSubscriptionReceivableMember2025-07-012025-09-300001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001191070us-gaap:WarrantMember2025-07-012026-03-310001191070neup:OptionsToPurchaseCommonStockMember2026-01-012026-03-310001191070neup:CancerStemCellTechnologyMember2025-07-012026-03-310001191070us-gaap:RetainedEarningsMember2025-10-012025-12-3100011910702025-09-300001191070srt:MaximumMember2026-01-012026-03-310001191070us-gaap:AdditionalPaidInCapitalMember2025-06-300001191070neup:OptionsToPurchaseCommonStockMember2024-07-012025-03-3100011910702024-06-300001191070neup:ContingentConsiderationInABusinessCombinationMember2025-03-3100011910702026-03-310001191070us-gaap:AdditionalPaidInCapitalMember2025-09-300001191070neup:FreestandingFinancialInstrumentsAccompanyingWarrantLiabilityMember2025-03-310001191070us-gaap:RetainedEarningsMember2026-01-012026-03-3100011910702025-01-012025-03-310001191070neup:ContingentConsiderationInABusinessCombinationMember2025-07-012026-03-310001191070us-gaap:CommonStockMember2025-03-3100011910702024-10-012024-12-310001191070neup:OptionsToPurchaseCommonStockMember2025-07-012026-03-310001191070us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001191070neup:ContingentConsiderationInABusinessCombinationMember2024-07-012025-03-310001191070us-gaap:RetainedEarningsMember2025-07-012025-09-3000011910702024-12-310001191070srt:MaximumMember2024-07-012025-03-310001191070neup:WGPartnersLLPMember2026-01-012026-03-310001191070neup:DrSpyrosPapapetropoulosMember2025-07-012026-03-310001191070us-gaap:AdditionalPaidInCapitalMember2025-12-310001191070us-gaap:RetainedEarningsMember2025-09-300001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001191070neup:ContingentConsiderationInABusinessCombinationMember2024-06-300001191070neup:WGPartnersLLPMember2024-07-012025-03-310001191070neup:RightsPlanMemberus-gaap:PreferredStockMember2025-07-012026-03-310001191070us-gaap:WarrantMember2026-03-310001191070neup:WarrantsToPurchaseCommonStockMember2024-07-012025-03-310001191070us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-06-3000011910702024-07-012024-09-300001191070us-gaap:RetainedEarningsMember2024-12-310001191070us-gaap:AdditionalPaidInCapitalMember2025-03-3100011910702026-01-012026-03-3100011910702025-12-3100011910702025-03-310001191070neup:WGPartnersLLPMember2026-01-192026-01-190001191070neup:BionomicsIncMember2025-07-012026-03-310001191070us-gaap:CommonStockMember2025-12-3100011910702025-10-250001191070neup:CancerStemCellTechnologyMember2025-06-300001191070neup:CancerStemCellTechnologyMember2025-03-310001191070neup:WGPartnersLLPMember2023-12-012023-12-310001191070neup:FreestandingFinancialInstrumentsAccompanyingWarrantLiabilityMember2024-07-012025-03-310001191070neup:WGPartnersLLPMember2026-01-200001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001191070neup:ContingentConsiderationInABusinessCombinationMember2025-06-300001191070neup:DanforthAdvisorsMember2024-07-012025-03-310001191070neup:FreestandingFinancialInstrumentsAccompanyingWarrantLiabilityMember2026-03-310001191070us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001191070neup:FreestandingFinancialInstrumentsAccompanyingWarrantLiabilityMember2025-07-012026-03-310001191070neup:CancerStemCellTechnologyMember2024-06-300001191070us-gaap:RestrictedStockUnitsRSUMember2025-07-012026-03-3100011910702024-09-300001191070us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001191070neup:CancerStemCellTechnologyMember2024-07-012025-03-310001191070us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001191070neup:WGPartnersLLPMember2026-01-202026-01-200001191070us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-310001191070neup:FreestandingFinancialInstrumentsAccompanyingWarrantLiabilityMember2025-06-300001191070neup:TwoThousandTwentyFourEquityIncentivePlanMember2026-03-310001191070neup:WGPartnersLLPMember2025-01-012025-03-31xbrli:purexbrli:sharesiso4217:USDiso4217:USDxbrli:shares\n\n \n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, DC 20549\n\n \n\n \n\nFORM 10-Q\n\n \n\n \n\n(Mark One)\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from _________________ to _________________\n\nCommission File Number: 001-41157\n\n \n\n \n\nNeuphoria Therapeutics Inc.\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n \n\nDelaware\n\n99-3845449\n\n(State or other jurisdiction of\n\n \n\n(I.R.S. Employer\n\nincorporation or organization)\n\n \n\nIdentification No.)\n\n \n\n \n\n \n\n \n\n \n\n \n\n100 Summit Drive, Burlington, Massachusetts\n\n \n\n01803\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\n(781) 730-6665\n\n(Registrant’s telephone number, including area code)\n\n \n\n \n\n \n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\n\nSymbol(s)\n\n \n\nName of each exchange on which registered\n\nCommon Stock, $0.00001 par value per share\n\n \n\nNEUP\n\n \n\nThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such file`s). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\n \n\nEmerging growth company\n\n \n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nIndicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐\n\nAs of May 14, 2026, there were 5,404,551 shares of the registrant’s common stock issued and outstanding.\n\n`\n\n \n\n \n\nTable of Contents\n\n \n\n \n\n \n\nPage\n\n \n\n[Basis of Presentation](#basis_of_presentation)\n\nii\n\n \n\n[Cautionary Note Regarding Forward-Looking Statements](#cautionary_note)\n\niii\n\n \n\n \n\n \n\nPART I.\n\n[FINANCIAL INFORMATION](#part_i)\n\n1"}